(Hong Kong / Beijing / Shanghai Comprehensive News) China is striving for Pfizer's permission to produce and distribute PAXLOVID in local pharmaceuticals in local production and distribution of crown disease oral drugs.At the same time, the first messenger ribonic acid (MRNA) coronary vaccine developed by Chinese pharmaceutical vendors has entered the trial production stage.
According to Reuters, anonymous sources said that China began negotiations with Paxlovid's Paxlovid generic drugs in China at the end of December last year.The negotiations are led by the China National Drug Administration, and strive to finalize the clause of this license before the Lunar New Year (January 22) this year (January 22).
Sources revealed that at the end of last year, the State Drug Administration had discussed with several domestic pharmaceutical companies to discuss the production preparation of PAXLOVID generic drugs and suggested that they prepare for relevant procedures.Both Zhejiang Huahai Pharmaceuticals and Hebei Shiyao Group participated in the discussion.Huahai Pharmaceutical signed an agreement with Pfizer in August last year to produce PaxLovid, which is only used in mainland China.The Stone Medicine Group is a potential MRNA vaccine developer.
Candidates such as Huahai and Stone Medicine have begun testing before the listing of generic drugs.It is expected that the two companies will submit the test results to the Drug Administration later in the later January.
Clinical trials show that PaxLovid can reduce the hospitalization rate of high -risk patients with crown disease by about 90 %.Crown disease infection cases surge in China, but inadequate antiviral drugs, PAXLOVID is in short supply in China.
According to the announcement of the Chinese Pharmaceutical Merchants Kangxino Biological Website on Thursday (January 5), the company's first MRNA coronary vaccine has entered the trial production stage. This will be the first batch of vaccines developed by China using MRNA technologyOne is expected to have a production capacity of 100 million doses in the first stage.
Kangshino said the vaccine will be targeted at Omikon virus.This is a mutant strain that caused most of the infectious cases after China's loosening and strict prevention and control measures in December last year.
Omikon virus and its variants are highly contagious, but China currently does not have a vaccine against Omikon and its variant virus.The inactivation of most Chinese injections cannot prevent Omikon's spread.
